Clinical trials: Human Papillomavirus Virus
Infections, Papillomavirus
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
This study is designed to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in pre-teen and adolescent female subjects aged 9 - 17 years.
- Trial name
- NCT00996125
- Testing
- CervarixTM, Control
- Where
- China
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Herpesvirus 2, Human
Male Circumcision for HIV Prevention in Rakai, Uganda
Circumcision in HIV unifected men may reduce the likelihood of becoming infected with HIV, reduce sexually transmitted infections (STIs) in men, not engender increases in sexual risk behaviors, and be acceptable to men as a…
- Conditions
- HIV Infections, Herpesvirus 2, Human, Syphilis, Genital Diseases, Male
- Trial name
- NCT00425984
- Testing
- Adult male circumcision
- Where
- Uganda
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Papillomavirus
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Background: Most symptoms of human papillomaviruses (HPV) infection, do not cause serious health problems, but some do. As HPV can cause uncontrolled growth of infected cells, some people can develop benign skin lesions, larger…
- Trial name
- NCT05026138
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Cancer
Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer
RATIONALE: Vaccines made from human papillomavirus may make the body build an immune response to and kill cervical cancer cells. Combining vaccine therapy with surgery may be a more effective treatment for cervical cancer.
- Trial name
- NCT00002916
- Testing
- human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide, adjuvant therapy
- Where
- 10 sites in Austria, France and 5 more
- Volunteers
- 44 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cervical Cancer Screening, HPV Infection
Risk of Cervical Cancer Following Incident, Persistent and History-unknown HPV Detection
The goal of this register-based retrospective observational study is to understand the risk of cervical cancer following incident, persistent and history-unknown HPV detection by HPV genotype in healthy women participating in…
- Trial name
- NCT07850128
- Testing
- No Intervention: Observational Cohort
- Where
- Sweden
- Volunteers
- 130,000 people
- Sponsor
- Karolinska Institutet
Cervical Intraepithelial Neoplasia
Recurrence in High-grade Lesions After Conization
Objectives: To identify factors associated with disease recurrence in patients with high-grade cervical intra-epithelial neoplasia (CIN) undergoing large loop excision of the transformation zone (LLETZ).
- Trial name
- NCT02540421
- Where
- Brazil
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Faculdade de Medicina do ABC
HPV Infections
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine type-specific genital disease among…
- Trial name
- NCT00834106
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,006 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Carcinoma, Human Papilloma Virus (HPV)
Leveraging Project ECHO for Improved Cervical Cancer Screening in Ethiopia
Project TICHILALECH ("she can" in Amharic), a five-year, implementation science study, is focused on improving cervical cancer screening, triage, and treatment and integration with human immunodeficiency virus (HIV) care at five…
- Trial name
- NCT07678047
- Testing
- TICHILALECH ECHO
- Where
- Ethiopia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Head and Neck Cancer, Precancerous Condition
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT01302834
- Testing
- cetuximab, cisplatin, IMRT
- Where
- 185 sites in United States, Canada
- Volunteers
- 987 people
- Sponsor
- Radiation Therapy Oncology Group
Human Papilloma Virus, Hiv
Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients
Patients with immunodeficiencies are at increased risk of developing persistent HPV infection and as such HPV-related disease (genital warts and cancer).
- Conditions
- Human Papilloma Virus, Hiv, Organ Transplants
- Trial name
- NCT03525210
- Testing
- 9-valent HPV vaccine
- Where
- Belgium
- Volunteers
- 271 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
HPV16+ Squamous Cell Carcinoma
A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)
The researchers are doing this study to find out if HB-202/HB-201 is a feasible treatment for people with HPV 16-positive head and neck squamous cell cancer (HPV 16+ HNSCC) who have received standard treatment for their disease…
- Trial name
- NCT06373380
- Testing
- HB-200
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HPV Vaccination, Uptake Vaccination
PREVENT HPV -Related Cancers Trial
This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West.
- Conditions
- HPV Vaccination, Uptake Vaccination, Series Completion
- Trial name
- NCT07217145
- Testing
- PREVENT
- Where
- United States
- Volunteers
- 1,455 people, healthy volunteers welcome
- Sponsor
- University of Utah
Head and Neck Squamous Cell Carcinoma
Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
This is a Phase II trial of definitive chemoradiotherapy (CTRT) given with the protease inhibitor,Nelfinavir (NFV), in patients with locally advanced head and neck.
- Trial name
- NCT02207439
- Testing
- Nelfinavir (Viracept®) 1250 mg, Chemoradiation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Penile Cancer, Anal Cancer
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.
- Conditions
- Penile Cancer, Anal Cancer, PIN-1, PIN-2
- Trial name
- NCT05518201
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Incident HPV16, 18, 31, 33, 45, 52 or 58 Infection
Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening
This study aims to evaluate the vaccine effectiveness of 1 dose the nonavalent human papillomavirus (HPV) vaccine against HPV16, 18, 31, 33, 45, 52, and 58 infection among young adult women in Sweden participating in a nationwide…
- Trial name
- FASTER1DOSE (NCT07314307)
- Testing
- Gardasil 9 2 dose regimen
- Where
- Sweden
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols.
- Trial name
- PATHOS (NCT02215265)
- Testing
- Cisplatin, Postoperative radiotherapy
- Where
- 57 sites in United States, Australia and 3 more
- Volunteers
- 1,269 people
- Sponsor
- Lisette Nixon
Health Behavior
An RCT Promoting HPV Vaccination Among Chinese MSM
Objectives: To evaluate efficacies of two online and theory-based interventions [HC: health communication only and HC-MI health communication plus motivational interviewing (MI)] in increasing uptake of three doses of HPV…
- Trial name
- NCT03286907
- Testing
- Online videos, Online videos and MI, Control group
- Where
- Hong Kong
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Human Papillomavirus
Detection of Human Papillomavirus in Polymerase Chain for Suspicious Lesions of the Amygdala: Concordance Smear-Biopsy
Multicentre prospective study of concordance between two tissue sampling modes (smear / biopsy), which applies the same diagnostic method (PCR).
- Trial name
- HPV-BIOFRO (NCT02656576)
- Testing
- Tonsil Biopsy, Smear
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Toulouse
Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Based on evidence that the local anesthetic lidocaine may have anticancer effects, this study will assess the safety and efficacy of intratumoral lidocaine injection at the time of direct laryngoscopy prior to TransOral Robotic…
- Conditions
- Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer, Human Papilloma Virus, Squamous Cell Carcinoma
- Trial name
- 856397 (NCT06747390)
- Testing
- Lidocaine 1% Injectable Solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ryan Carey
Squamous Cell Carcinoma of the Head and Neck
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
This is an open label pilot study evaluating the pharmacodynamics and safety of single agent olaparib administered at 300mg bid (twice a day) for 14 days orally in patients with human papillomavirus (HPV) -positive and human…
- Trial name
- NCT02686008
- Testing
- Olaparib
- Sponsor
- Yale University